Dexmedetomidine
BXCL501-201
Phase 2 small_molecule completed
Quick answer
Dexmedetomidine for Opioid Withdrawal is a Phase 2 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioXcel Therapeutics
- Indication
- Opioid Withdrawal
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed